# Bladder Capacity as Objective Measure of Intravesical Treatment of Newly Diagnosed IC

> **NCT05223244** · PHASE4 · COMPLETED · sponsor: **Endeavor Health** · enrollment: 83 (actual)

## Conditions studied

- Interstitial Cystitis
- Painful Bladder Syndrome

## Interventions

- **DRUG:** bupivacaine, triamcinolone, and heparin (BTH)
- **DRUG:** dimethyl sulfoxide (DMSO)

## Key facts

- **NCT ID:** NCT05223244
- **Lead sponsor:** Endeavor Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-01
- **Primary completion:** 2019-04-01
- **Final completion:** 2020-03-30
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2022-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05223244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05223244, "Bladder Capacity as Objective Measure of Intravesical Treatment of Newly Diagnosed IC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05223244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*